SEI Investments
ECYT

SEI Investments’s Endocyte, Inc. Common Stock ECYT Stock Holding History

SEI Investments’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-427
Closed -$1K – 3399
2017
Q1 		$1K Sell
427
-2,218
-84% -$5.13K ﹤0.01% 2868
2016
Q4 		$7K Buy
+2,645
New +$7.59K ﹤0.01% 2543

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return

SEI Investments's ECYT Position: Q2 2017 in Review

SEI Investments sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2017, closing a stake of 427 shares — an estimated $1K sold.

SEI Investments first reported a position in ECYT in Q4 2016 and held it in 2 quarters. The position peaked at $7K in Q4 2016. 75 funds tracked by Wall St. Rank hold ECYT as of Q2 2017.

  • SEI Investments reported no remaining Endocyte, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • SEI Investments sold 427 Endocyte, Inc. Common Stock shares in Q2 2017, an estimated $1K.
  • SEI Investments first reported a position in Endocyte, Inc. Common Stock in Q4 2016 and held it in 2 quarters.
  • SEI Investments's Endocyte, Inc. Common Stock position peaked at $7K in Q4 2016.
  • 75 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2017.

Based on SEI Investments's 13F filing for Q2 2017, filed 31 Jul 2017.